These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24999598)

  • 1. Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass.
    Staaf J; Harbst K; Lauss M; Ringnér M; Måsbäck A; Howlin J; Jirström K; Harland M; Zebary A; Palmer JM; Ingvar C; Olsson H; Newton-Bishop J; Hansson J; Hayward N; Gruis N; Jönsson G
    J Invest Dermatol; 2014 Dec; 134(12):3000-3003. PubMed ID: 24999598
    [No Abstract]   [Full Text] [Related]  

  • 2. Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study.
    Zebary A; Omholt K; van Doorn R; Ghiorzo P; Harbst K; Hertzman Johansson C; Höiom V; Jönsson G; Pjanova D; Puig S; Scarra GB; Harland M; Olsson H; Egyhazi Brage S; Palmer J; Kanter-Lewensohn L; Vassilaki I; Hayward NK; Newton-Bishop J; Gruis NA; Hansson J;
    J Invest Dermatol; 2014 Jan; 134(1):287-290. PubMed ID: 23771122
    [No Abstract]   [Full Text] [Related]  

  • 3. Longitudinal assessment of the nevus phenotype in a melanoma kindred.
    Florell SR; Meyer LJ; Boucher KM; Porter-Gill PA; Hart M; Erickson J; Cannon-Albright LA; Pershing LK; Harris RM; Samlowski WE; Zone JJ; Leachman SA
    J Invest Dermatol; 2004 Sep; 123(3):576-82. PubMed ID: 15304099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma: What do all the mutations mean?
    Davis EJ; Johnson DB; Sosman JA; Chandra S
    Cancer; 2018 Sep; 124(17):3490-3499. PubMed ID: 29663336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.
    García-Casado Z; Traves V; Bañuls J; Niveiro M; Gimeno-Carpio E; Jimenez-Sanchez AI; Moragón M; Onrubia JA; Oliver V; Kumar R; Nagore E
    Br J Dermatol; 2015 Apr; 172(4):1128-31. PubMed ID: 25385688
    [No Abstract]   [Full Text] [Related]  

  • 6. Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations.
    Jovanovic B; Egyhazi S; Eskandarpour M; Ghiorzo P; Palmer JM; Bianchi Scarrà G; Hayward NK; Hansson J
    J Invest Dermatol; 2010 Feb; 130(2):618-20. PubMed ID: 19759551
    [No Abstract]   [Full Text] [Related]  

  • 7. Nevus distribution in a Utah melanoma kindred with a temperature-sensitive CDKN2A mutation.
    Florell SR; Meyer LJ; Boucher KM; Hart M; Cannon-Albright LA; Harris RM; Grossman D; Samlowski WE; Zone JJ; Brinton JP; Leachman SA
    J Invest Dermatol; 2005 Dec; 125(6):1310-2. PubMed ID: 16354203
    [No Abstract]   [Full Text] [Related]  

  • 8. BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.
    Frank GA; Aleksakhina SN; Zavalishina LE; Kekeyeva TV; Venina AR; Ivantsov AO; Mitiushkina NV; Moiseyenko AV; Pfeifer W; Strelkova TN; Imyanitov EN
    Melanoma Res; 2016 Oct; 26(5):442-7. PubMed ID: 27433783
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetic profile of naïve untreated primary cutaneous melanomas with a negative sentinel lymph node.
    Yang K; Oh KS; Mahalingam M
    Clin Exp Dermatol; 2020 Dec; 45(8):1059-1062. PubMed ID: 32484959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased melanocytic nevi and nevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree.
    Florell SR; Meyer LJ; Boucher KM; Grossman D; Cannon-Albright LA; Harris RM; Samlowski WE; Zone JJ; Leachman SA
    J Invest Dermatol; 2008 Aug; 128(8):2122-5. PubMed ID: 18337833
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.
    Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G
    Pigment Cell Melanoma Res; 2008 Dec; 21(6):700-9. PubMed ID: 18983535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular profile of metastatic melanoma in Australia.
    Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
    Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unfolding the mutational landscape of human melanoma.
    Davar D; Lin Y; Kirkwood JM
    J Invest Dermatol; 2015 Mar; 135(3):659-662. PubMed ID: 25666674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial melanoma: a complex disorder leading to controversy on DNA testing.
    de Snoo FA; Bergman W; Gruis NA
    Fam Cancer; 2003; 2(2):109-16. PubMed ID: 14574160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
    Goel VK; Ibrahim N; Jiang G; Singhal M; Fee S; Flotte T; Westmoreland S; Haluska FS; Hinds PW; Haluska FG
    Oncogene; 2009 Jun; 28(23):2289-98. PubMed ID: 19398955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study.
    Potjer TP; van der Stoep N; Houwing-Duistermaat JJ; Konings IC; Aalfs CM; van den Akker PC; Ausems MG; Dommering CJ; van der Kolk LE; Maiburg MC; Spruijt L; Wagner A; Vasen HF; Hes FJ
    BMC Res Notes; 2015 Jun; 8():264. PubMed ID: 26111702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue-white veil.
    Gouillon L; Perier-Muzet M; Amini-Adle M; Poulalhon N; Debarbieux S; Boespflug A; Balme B; Depaepe L; Harou O; Lopez J; Bringuier PP; Ferraro-Peyret C; Maucort-Boulch D; Robinson P; Thomas L; Dalle S
    J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):e57-e59. PubMed ID: 31442328
    [No Abstract]   [Full Text] [Related]  

  • 19. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of BRAF and KIT mutations in Japanese melanoma patients.
    Ashida A; Uhara H; Kiniwa Y; Oguchi M; Murata H; Goto Y; Uchiyama A; Ogawa E; Hayashi K; Koga H; Okuyama R
    J Dermatol Sci; 2012 Jun; 66(3):240-2. PubMed ID: 22534474
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.